Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Polski Lek is a prominent Polish pharmaceutical company that specializes in the production and distribution of dietary supplements, medical devices, and over-the-counter (OTC) medications. The company is best known for its market-leading brands, including Plusssz, the top effervescent vitamin brand in Poland, and Litorsal, a leading hydration product. In 2021, Polski Lek was acquired by the Maspex Group, one of the largest food and beverage conglomerates in Central and Eastern Europe, which significantly expanded its distribution capabilities. The company maintains high-quality manufacturing standards, utilizing modern production lines for effervescent tablets, capsules, and traditional tablets. Its product portfolio is designed to support various health needs, ranging from immune system enhancement to electrolyte replenishment and bone health. Polski Lek continues to be a key player in the Polish pharmacy and retail sectors, focusing on consumer-driven health solutions.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Polski Lek.